Sabbatini, Paul

Publications

Sort by

Co-Author Network

selected publications

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2019 Academic Article GET IT
Times cited: 30
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 Academic Article GET IT
Times cited: 5
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. 2016 GET IT
Times cited: 218
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. Cancers. 2016 Academic Article GET IT
Times cited: 38
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016 Academic Article GET IT
Times cited: 9
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 1340
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug discovery today. 2015 Academic Article GET IT
Times cited: 121
Ovarian cancer, version 2.2013. 2013 GET IT
Times cited: 113
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 49
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 112
Ovarian cancer, version 3.2012. 2012 GET IT
Times cited: 79
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 99
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 209
Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery. AJR. American journal of roentgenology. 2012 Academic Article GET IT
Times cited: 21
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 39
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 2
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 8
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 38
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer. 2011 Academic Article GET IT
Times cited: 16
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Review GET IT
Times cited: 20
Abagovomab for ovarian cancer. Expert opinion on biological therapy. 2011 Review GET IT
Times cited: 10
Epithelial ovarian cancer. 2011 GET IT
Times cited: 88
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 82
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 147
Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 9
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 89
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 34
Consolidation therapy in ovarian cancer: a clinical update. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Review GET IT
Times cited: 11
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 41
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 22
Epothilones: better or more of the same?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Editorial Article GET IT
Times cited: 7
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 17
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 184
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 12
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 48
Ovarian cancer. Clinical practice guidelines in oncology. 2008 GET IT
Times cited: 43
Cancer- and chemotherapy-induced anemia. 2008 GET IT
Times cited: 31
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up. Cancer. 2008 Academic Article GET IT
Times cited: 3
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 67
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 93
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 488
Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. American journal of obstetrics and gynecology. 2008 Academic Article GET IT
Times cited: 19
Re: "Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials". Gynecologic oncology. 2008 Letter GET IT
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. European journal of gynaecological oncology. 2008 Academic Article GET IT
Times cited: 16
Harnessing the immune system for ovarian cancer therapy. American journal of reproductive immunology (New York, N.Y. : 1989). 2008 Review GET IT
Times cited: 17
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 98
Cancer-related fatigue. Clinical Practice Guidelines in Oncology. 2007 GET IT
Times cited: 87
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 123
Immunologic approaches to ovarian cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Review GET IT
Times cited: 40
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 30
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Letter GET IT
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 16
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 91
A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 52
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 55
Ovarian cancer. Clinical practice guidelines in oncology. 2006 GET IT
Times cited: 15
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 61
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 64
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 56
Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 84
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 27
Consolidation for ovarian cancer in remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Editorial Article GET IT
Times cited: 19
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 34
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 5
p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 33
Cancer- and treatment-related anemia. Journal of the National Comprehensive Cancer Network : JNCCN. 2005 Academic Article GET IT
Times cited: 16
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 110
Patient online self-reporting of toxicity symptoms during chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 237
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecologic oncology. 2005 Academic Article GET IT
Times cited: 107
New agents for the treatment of ovarian cancer: the next generation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005 Review GET IT
Times cited: 11
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 107
Ovarian cancer clinical practice guidelines. 2004 GET IT
Times cited: 2
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecologic oncology. 2004 Review GET IT
Times cited: 18
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004 Academic Article GET IT
Times cited: 120
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 280
Early detection and prognosis of ovarian cancer using serum YKL-40. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 119
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 18
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 39
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 6
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 123
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 50
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 39
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 78
Anemia clinical practice guidelines in oncology. 2003 GET IT
Times cited: 2
Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. 2002 GET IT
Times cited: 14
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 408
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 587
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. 2002 GET IT
Times cited: 100
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 96
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 111
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 20
Endometrial stromal sarcoma: objective response to letrozole. 2001 GET IT
Times cited: 101
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 19
Complications associated with intraperitoneal chemotherapy catheters. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 85
Contribution of anemia to fatigue in the cancer patient. Oncology (Williston Park, N.Y.). 2000 Review GET IT
Times cited: 8
NCCN Practice Guidelines for Cancer-Related Fatigue. 2000 GET IT
Times cited: 409
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecologic oncology. 2000 Academic Article GET IT
Times cited: 7
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. International journal of cancer. 2000 Academic Article GET IT
Times cited: 123
Advanced ovarian cancer. Current treatment options in oncology. 2000 Review GET IT
Times cited: 27
The relationship between anemia and quality of life in cancer patients. The oncologist. 2000 Review GET IT
Times cited: 45
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecologic oncology. 1999 Academic Article GET IT
Times cited: 21
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 203
Implementation of disease management guidelines in patients with advanced ovarian cancer. Seminars in oncology. 1999 Review GET IT
Times cited: 2
Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Current opinion in obstetrics & gynecology. 1999 Review GET IT
Times cited: 4
Chemotherapy in gynecologic cancer. Current opinion in oncology. 1998 Review GET IT
Times cited: 4
Salvage therapy for ovarian cancer. Oncology (Williston Park, N.Y.). 1998 Review GET IT
Times cited: 26
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. The Journal of clinical endocrinology and metabolism. 1996 Academic Article GET IT
Times cited: 210

more ...

less ...

Background

education and training

M.D., University of Mississippi School of Medicine 1989
B.A., University of Mississippi 1985

Contact

full name

Paul Sabbatini

VIVO Weill Cornell Medical College

Paul Sabbatini Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name